摘要
Abstract
Objective To investigate the clinical efficacy of intravitreal ranibizumab injection combined with argon laser photocoagulation in treating ischemic central retinal vein occlusion ( CRVO ) and its complications. Methods 78 patients ( 78 eyes ) with ischemic CRVO in our hospital from February 2013 to February 2014 were divided into the control group and the observation group according to the method of the random number table, 39 cases in each group. The control group was given the argon laser photocoagulation treatment, while the observation group received the therapy of laser photocoagulation combined with intravitreal ranibizumab injection. The best cor-rected visual acuity and macular edema ( ME ) regression before and in 1 week, 1 month and 6 months after treatment were observed in the two groups. Results The best corrected visual acuity after 1-week, 1-month and 6-month treatment in the observation group was better than that before treatment and the control group ( P﹤0. 05 );the best corrected visual acuity in the observation group had no sta-tistically significant difference between after 3-month and 6-month treatment. The ME regression after 1-month, 3-month, 6-month treatment in the observation group was better than that in the control group ( P﹤0. 05 ) . Conclusion Argon laser photocoagulation com-bined with intravitreal ranibizumab injection can improve the vision in the patients with ischemic CRVO, promote obvious absorption of retinal hemorrhages and exudates, and the regression of ME, which has good effect and is worthy of clinical promotion.关键词
雷珠单抗/视网膜光凝/缺血型视网膜中央静脉阻塞/黄斑水肿/临床疗效Key words
ranibizumab/ischemic central retinal vein occlusion/macular edema/retinal photocoagulation/clinical efficacy分类
医药卫生
